Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $82.16M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.03M
Average 0.25M
RLYB Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Rallybio CorporationNASDAQ: RLYB
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 557.6% from a year ago
Other current assets stood at $5.73M at the end of Q1 FY2026, up 557.6% from a year earlier and down 12.0% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Other current assets amounted to 10.5% of total assets at the end of Q1 FY2026, up 9.0 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +557.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.52M USD
- Year-over-year change
- +153.0%
- 4-year CAGR
- +58.9%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.52M | +153.0% |
| FY2024 | 2024-12-31 | 995K | -51.6% |
| FY2023 | 2023-12-31 | 2.05M | +95.6% |
| FY2022 | 2022-12-31 | 1.05M | +165.8% |
| FY2021 | 2021-12-31 | 395K | — |
Other Current Assets vs competitors
How RLYB compares with its peers on the latest reported figures
- RLYB's Mar 2026 other current assets of $5.73M is the 2nd highest of the 4 companies compared; the peer median is $3.08M.
- Its year-over-year change of +557.6% is the 2nd highest of 4, against a peer median of +197.7%.
- Other current assets amounts to 10.5% of total assets for RLYB, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.45M | +6836.6% | +259.0% | 10.1% | |
| Mar 2026 | $5.73M | +557.6% | +33.8% | 10.5% | |
| Jun 2026 | $3.08M | +197.7% | -45.2% | 3.1% | |
| Mar 2026 | $1.77M | -16.2% | +15.4% | 1.3% | |
| Peer median (excluding RLYB) | $3.08M | +197.7% | +15.4% | 3.1% | |
Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 175.33M | 56.96M | 24.49M | 13.9M | 31.37M |
| Short-term Investments | 0 | 112.04M | 85.44M | 51.61M | 23.36M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 395K | 1.05M | 2.05M | 995K | 2.52M |
| Total Current Assets | 180.87M | 179.5M | 114.79M | 67.84M | 61.25M |
| Property, Plant & Equipment (Net) | 511K | 909K | 592K | 267K | 198K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 805K | 30K | 239K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 810K |
| Total Non-current Assets | 1.32M | 939K | 831K | 267K | 1.01M |
| Total Assets | 182.19M | 180.44M | 115.62M | 68.11M | 62.26M |
| Account Payables | 603K | 1.11M | 976K | 278K | 126K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 848K | 212K |
| Other Current Liabilities | 2.99M | 4.7M | 3.17M | 3.1M | 1.46M |
| Total Current Liabilities | 6.55M | 10.74M | 9.26M | 6.24M | 4.22M |
| Long-term Debt | 0 | 374K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 212K | 0 |
| Other Non-current Liabilities | 32K | (374K) | 0 | 0 | 0 |
| Total Non-current Liabilities | 32K | 374K | 173K | 212K | 82K |
| Total Liabilities | 6.58M | 11.12M | 9.44M | 6.45M | 4.31M |
| Common Stock | 3K | 4K | 4K | 4K | 4K |
| Retained Earnings | (94.03M) | (160.68M) | (235.25M) | (293.02M) | (302M) |
| Accumulated OCI | 0 | (214K) | 15K | 68K | 18K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 175.6M | 169.32M | 106.18M | 61.65M | 57.96M |
| Total Debt | 0 | 555K | 392K | 154K | 176K |
| Net Debt | (175.33M) | (56.4M) | (24.1M) | (13.75M) | (31.2M) |
Rallybio Corporation
NASDAQ:RLYB
Intrinsic Alpha fair value
Locked
Current Price
$15.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.